The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Preliminary results with nuvisertib plus momelotinib in patients with R/R myelofibrosis
In this video, Claire Harrison, MD, FRCP, FRCPath, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, discusses the preliminary results from a Phase I/II study (NCT04176198) evaluating nuvisertib, an oral investigational selective PIM1 inhibitor, in combination with momelotinib in patients with relapsed/refractory (R/R) myelofibrosis (MF). Prof. Harrison highlights that the clinical activity of this combination is promising, and the regimen is well-tolerated. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
At the ASH meeting 2025, there are a number of kinds of firsts in the MPN field, and one of those was the first combination data that came from momelotinib with another agent. And the other agent is nuvisertib, which is a PIM1 kinase inhibitor. Now, we’ve seen some data already with nuvisertib, both alone and a little bit of data in combination with ruxolitinib...
At the ASH meeting 2025, there are a number of kinds of firsts in the MPN field, and one of those was the first combination data that came from momelotinib with another agent. And the other agent is nuvisertib, which is a PIM1 kinase inhibitor. Now, we’ve seen some data already with nuvisertib, both alone and a little bit of data in combination with ruxolitinib. So this information, even though it’s only preliminary data, is really important and exciting. Momelotinib is a great combination partner. It can be tolerated in patients who are a bit more cytopenic, so anemic and thrombocytopenic. And nuvisertib potentially improves symptoms, which is maybe a little bit of a gap with momelotinib. It also improves spleen responses and in some patients, hemoglobin and platelets. So what we can say from this meeting is this looks like a promising combination. It was well tolerated and we were seeing some positive impacts for patients. So it’s a really good study to think about including patients on if you’re looking for something more than just a JAK inhibitor.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
